PBL-001NCT07921615
QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II Study
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (1)
Arms and interventions
Eligible patients who meet the inclusion/exclusion criteria will receive QLS4131 combined with the Isa-V-CHOP regimen after enrollment, with each cycle lasting 21 days; efficacy will be assessed after Cycles 2 and 4 and after completion of Cycle 6. After completing 6 cycles and the primary endpoint assessment, patients with advanced-stage disease (Ann Arbor stage III-IV) may receive autologous hematopoietic stem cell transplantation or QLS4131 monotherapy maintenance for 6 cycles; patients with limited-stage disease (stage I-II) may be considered for local radiotherapy.
Drugs: QLS4131 combined with Isa-V-CHOP